Checkpoint Therapeutics Receives Pediatric Investigational Plan Waivers for Cosibelimab from the European Medicines Agency and U.K. Medicines &…

Posted: May 15, 2022 at 2:13 am

Waivers remove requirement to conduct pediatric clinical studies to support cosibelimab marketing authorization applications in Europe Waivers remove requirement to conduct pediatric clinical studies to support cosibelimab marketing authorization applications in Europe

Read the original post:
Checkpoint Therapeutics Receives Pediatric Investigational Plan Waivers for Cosibelimab from the European Medicines Agency and U.K. Medicines &...

Related Posts